Boehringer Ingelheim recentlyannounced a collaboration with Weill Cornell Medicine to identify new treatment approaches forchronic obstructive pulmonary disease (COPD)in order to develop novel treatments that could possibly halt or even reverse the progression of the disease process. The new, three-year collaboration combines Weill Cornell Medicines Department of Genetic Medicines unique understanding of chronic airway diseases and experience in the investigation of novel therapeutic concepts for airway repair with Boehringer Ingelheims expertise in the discovery and development of new therapies for respiratory diseases. This collaboration is the second collaboration between Boehringer Ingelheim and Weill Cornell Medicine, following prior work in inflammatory bowel disease (IBD). <\/p>\n
Chronic lower respiratory diseases, which include COPD, are the third leading cause of death in the United States,and approximately 15million Americans have been told by a healthcare provider that they have COPD.It cannot be cured and current treatment approaches focus on bronchodilation, reducing symptoms and preventing exacerbations to decelerate the downward spiral of the disease.The goal is to help patients keep as active as possible and overall, improve their quality of life. <\/p>\n
Our continuous search for molecular drivers of chronic obstructive airway diseases has revealed novel repair mechanisms that warrant further investigation of their potential as therapeutic approaches, said Dr. Ronald G. Crystal, Chairman of Genetic Medicine at Weill Cornell Medicine and lead investigator in the new collaboration. We will look to further expand our knowledge about progressive airway destruction in close collaboration with Boehringer Ingelheim and focus on promising therapeutic concepts with the potential to slow down or halt progressive airway damage in patients with COPD. <\/p>\n
We are delighted to work with Dr. Crystal at Weill Cornell Medicine, who is one of the leading scientists in severe progressive airway diseases worldwide, said Dr. Clive R. Wood, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. The scientists at Weill Cornell Medicine and Boehringer Ingelheim will work hand in hand to translate new discoveries into drug discovery and development programs at Boehringer Ingelheim. The new collaboration is an excellent example of our unique partnering approach and our focus on early innovation, underscoring our ambition to develop the next generation of medical treatments for patients with COPD. <\/p>\n
Boehringer Ingelheim is combining a focus on cutting-edge science with a long-term view enabling the company to create a stable environment for the development of the next generation of medical breakthroughs. This new project adds another building block in this long-term strategy to improve the lives of patients with high unmet medical needs. <\/p>\n
Weill Cornell's Office of BioPharma Alliances and Research Collaborations negotiated the three-year collaboration.The offices mission is to proactively generate, structure and market translational research alliances with industry in order to advance promising research projects that have commercial potential. For more information, contact Larry Schlossman atlas2041@med.cornell.eduor<\/a> at 212-746-6909. <\/p>\n About Boehringer Ingelheim in Respiratory <\/p>\n Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 the company has emerged as a leader in this disease area and has launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Boehringer Ingelheims focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life. <\/p>\n About Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation. <\/p>\n Boehringer Ingelheim is one of the worlds 20 leading pharmaceutical companies.Headquartered in Ingelheim, Germany, the company operates globally with 145affiliates and more than 47,000 employees.Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine. <\/p>\n Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit ourCorporate Social Responsibility Report. <\/p>\n In 2015, Boehringer Ingelheim achieved net sales of about $15.8B (14.8billioneuros). R&D expenditure corresponds to 20.3 percent of its net sales. <\/p>\n SOURCE: Boehringer Ingelheim Pharmaceuticals, Inc.<\/p>\n <\/p>\n See the rest here:<\/p>\n Boehringer Ingelheim And Weill Cornell Medicine Announce New ... - Clinical Leader<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Boehringer Ingelheim recentlyannounced a collaboration with Weill Cornell Medicine to identify new treatment approaches forchronic obstructive pulmonary disease (COPD)in order to develop novel treatments that could possibly halt or even reverse the progression of the disease process. The new, three-year collaboration combines Weill Cornell Medicines Department of Genetic Medicines unique understanding of chronic airway diseases and experience in the investigation of novel therapeutic concepts for airway repair with Boehringer Ingelheims expertise in the discovery and development of new therapies for respiratory diseases. This collaboration is the second collaboration between Boehringer Ingelheim and Weill Cornell Medicine, following prior work in inflammatory bowel disease (IBD). Continue reading